+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Addiction Disorders Drugs Market by Dosage Form, Drug Class, Product Type, Administration Route, Distribution Channel, End User - Global Forecast 2026-2032- Product Image
Addiction Disorders Drugs Market by Dosage Form, Drug Class, Product Type, Administration Route, Distribution Channel, End User - Global Forecast 2026-2032- Product Image
Sale

Addiction Disorders Drugs Market by Dosage Form, Drug Class, Product Type, Administration Route, Distribution Channel, End User - Global Forecast 2026-2032

  • Report

  • 182 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 5337785
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Addiction Disorders Drugs Market is projected to reach USD 22.31 Billion in 2026. It is expected to continue growing at a CAGR of 9.85%, reaching USD 39.33 Billion by 2032.

The addiction disorders drugs market sits at the intersection of urgent public health need, medication-assisted treatment expansion, and fast-changing policy. Demand is driven by opioid use disorder, alcohol use disorder, tobacco dependence, stimulant use disorder, and polysubstance use, with treatment strategies spanning agonists, partial agonists, antagonists, aversive agents, withdrawal management drugs, and relapse-prevention therapies.

Commercial opportunity is strongest where evidence-based pharmacotherapy is integrated with behavioral health, primary care, telehealth, and long-term recovery support. Market leaders are increasingly focused on long-acting injectable formulations, digital adherence support, expanded access models, overdose reversal medicines, and combination care pathways that improve retention, reduce relapse, and address comorbid mental health conditions.

Transformative Shifts in Addiction Treatment

The market is being reshaped by a shift from acute detoxification to chronic disease management. Addiction is increasingly treated as a relapsing medical condition requiring sustained pharmacotherapy, coordinated behavioral care, and measurable outcomes. This shift supports broader use of buprenorphine, methadone, naltrexone, acamprosate, disulfiram, nicotine replacement therapies, varenicline, cytisine where approved, and emerging candidates for stimulant and cannabis use disorders.

Regulatory and reimbursement changes are also changing access. In the U.S., the removal of the federal X-waiver requirement for buprenorphine prescribing expanded the eligible prescriber base, while many countries are revising harm-reduction, opioid agonist therapy, and take-home medication policies. At the same time, payers and public health systems are scrutinizing real-world evidence, adherence, diversion controls, safety monitoring, and total cost-of-care benefits.

Innovation is moving beyond conventional oral therapies. Long-acting injectables and implants support adherence and reduce daily dosing burden, while intranasal overdose reversal products have increased community-based emergency response capacity. The next competitive phase will favor organizations able to prove clinical durability, safety in complex populations, compatibility with behavioral health services, and interoperability with digital and community care models.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to create cumulative value across discovery, development, access, and patient support for addiction disorder medications. In drug discovery, AI-enabled target identification, molecular screening, and biomarker analysis can help prioritize candidates for conditions with limited approved pharmacologic options, including stimulant use disorder. In clinical development, machine learning can support trial design by identifying risk profiles, predicting dropout, strengthening site selection, and improving protocol feasibility.

AI is also influencing care delivery. Predictive analytics can flag relapse risk, overdose vulnerability, treatment discontinuation, and medication nonadherence when used with validated clinical data and appropriate privacy safeguards. Natural language processing may help health systems identify substance use patterns in clinical notes, while AI-supported digital therapeutics can reinforce behavioral interventions between visits and support care coordination across primary care, psychiatry, and community programs.

The cumulative impact will depend on governance. Algorithms used in addiction care must be clinically validated, bias-tested, explainable, and transparent because substance use disorders are closely linked to stigma, criminal justice exposure, unstable housing, and other social determinants of health. Organizations that combine AI with rigorous evidence generation, patient consent, cybersecurity, and regulatory-grade data practices will be better positioned to earn provider, payer, and patient trust.

Key Regional Insights

North America remains a central market for addiction disorders drugs because of high treatment demand, established medication-assisted treatment infrastructure, and significant public funding for opioid response. The United States has the deepest commercial ecosystem for buprenorphine, naltrexone, methadone services, naloxone, alcohol use disorder medications, and smoking cessation therapies, while Canada continues to expand supervised consumption, opioid agonist therapy, and safer supply discussions in response to toxic drug supply risks.

Europe shows strong policy support for harm reduction and opioid substitution treatment, particularly in Western and Northern European health systems. European public health frameworks support surveillance, prevention, and access to evidence-based treatment, although reimbursement and prescribing rules vary by country. Asia-Pacific presents a mixed but expanding opportunity, with Japan, Australia, South Korea, China, India, and ASEAN markets showing different levels of treatment availability, stigma reduction, tobacco control policy, mental health investment, and regulatory openness.

Latin America is gaining relevance as governments address alcohol dependence, tobacco use, and illicit drug-related harms, with Brazil and Mexico acting as important demand centers. The Middle East and Africa remain underpenetrated for addiction pharmacotherapy due to stigma, specialist shortages, limited reimbursement, and uneven harm-reduction infrastructure, but GCC countries are investing in specialized behavioral health services, and parts of Africa face rising need for accessible, low-cost treatment and overdose prevention support.

Key Group Insights

Within ASEAN, addiction disorder drug demand is shaped by large populations, variable regulatory approaches, and rising focus on mental health system capacity. Access remains uneven across member states, but urban hospital networks, tobacco control programs, and public health initiatives are creating pathways for pharmacotherapy adoption, particularly for alcohol, tobacco, and opioid-related conditions where policy permits evidence-based treatment.

The GCC is increasingly relevant as governments invest in modern healthcare infrastructure, specialized psychiatric care, and national addiction treatment initiatives. Cultural stigma remains a barrier, but centralized healthcare planning can accelerate adoption of evidence-based therapies when supported by reimbursement, clinician training, confidential care pathways, and integration with broader mental health reforms. The European Union offers one of the most structured policy environments, with coordinated surveillance and harm-reduction guidance supporting long-term treatment models and cross-country evidence sharing.

BRICS countries represent high-volume opportunity, led by China, India, and Brazil, but access depends on affordability, domestic manufacturing, public-sector procurement, and regulatory alignment with evidence-based treatment standards. G7 markets provide the strongest environment for premium formulations, long-acting injectables, evidence generation, overdose reversal access, and digital care integration. NATO countries overlap significantly with North American and European markets where defense, veteran, and public health systems increasingly recognize substance use disorders as workforce, family, and community health priorities.

Key Country Insights

The United States is the most influential country market due to high opioid-related morbidity, broad medication-assisted treatment use, and active regulatory pathways for overdose reversal and relapse-prevention products. Canada is expanding harm-reduction-linked treatment capacity and opioid agonist therapy access, while Mexico and Brazil represent important Latin American markets where public-sector access, tobacco control, and alcohol-related disease burden shape demand for addiction pharmacotherapy.

In Europe, the United Kingdom, Germany, France, Italy, and Spain support mature treatment systems with varying degrees of opioid substitution therapy, alcohol use disorder medication use, and smoking cessation reimbursement. Russia has a distinct treatment environment because opioid agonist therapy is restricted, affecting market access for standard opioid use disorder medications. Germany and France are especially important for evidence-based prescribing, reimbursement evaluation, specialist care networks, and structured addiction medicine services.

China and India offer large long-term potential because of population scale, tobacco burden, alcohol-related harms, and growing investment in mental health services, but adoption depends on regulation, stigma reduction, affordability, and physician training. Japan, Australia, and South Korea offer more advanced regulatory and reimbursement environments for selected therapies, with Australia notable for harm-reduction experience and opioid pharmacotherapy access, while Japan and South Korea offer opportunities in smoking cessation, alcohol treatment, and carefully regulated addiction medicine.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies that improve retention and reduce relapse, because adherence remains one of the most important barriers in addiction treatment. Long-acting injectables, depot formulations, abuse-deterrent delivery, overdose reversal products, and patient-centered dosing models should be supported with real-world evidence demonstrating fewer emergency visits, lower overdose risk, improved medication persistence, and stronger continuity of care.

Organizations should also build market access strategies around integrated care. Partnerships with primary care groups, community clinics, telehealth providers, behavioral health networks, pharmacies, harm-reduction programs, and correctional health systems can expand reach to populations that often remain outside traditional specialty treatment. Education for prescribers is essential, especially in markets where stigma and limited addiction medicine training constrain uptake.

Finally, leaders should invest in ethical AI, pharmacovigilance, and health equity. Evidence packages should include diverse populations, comorbid psychiatric conditions, pregnancy considerations where applicable, and social risk factors. Stakeholders that demonstrate safety, measurable outcomes, affordability, privacy protection, and responsible data use will be best positioned for payer acceptance and long-term public health relevance.

Research Methodology

This executive summary is based on secondary research from authoritative public health, regulatory, and scientific sources, including the World Health Organization, UN Office on Drugs and Crime, U.S. Centers for Disease Control and Prevention, U.S. Food and Drug Administration, European drug monitoring authorities, national health agencies, peer-reviewed medical literature, and published clinical guidelines.

The methodology emphasizes triangulation of epidemiology, treatment guidelines, regulatory developments, approved medication classes, policy reforms, harm-reduction practices, and regional access dynamics. Market interpretation focuses on verified disease burden, evidence-based pharmacotherapy adoption, reimbursement conditions, regulatory access, and innovation trends rather than unsupported projections.

Insights were synthesized through an industry lens, aligning clinical facts with commercial implications across regions, groups, and country markets. The analysis prioritizes data-backed statements, current treatment standards, observable policy shifts, and practical implications relevant to addiction disorders drugs.

Conclusion

The addiction disorders drugs market is evolving from fragmented treatment access toward integrated, evidence-based, and outcomes-driven care. Rising global burden, sustained overdose risk, alcohol-related harm, stimulant use concerns, and tobacco dependence continue to support demand for pharmacologic interventions that improve retention, prevent relapse, reduce withdrawal burden, and lower mortality.

Future progress will be shaped by long-acting formulations, expanded prescribing capacity, harm-reduction integration, overdose reversal access, AI-enabled patient support, and stronger real-world evidence. Organizations that combine clinical efficacy with affordability, privacy protection, equitable access, and partnerships across behavioral health ecosystems will be best positioned to lead in this high-need therapeutic area.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Addiction Disorders Drugs Market, by Dosage Form
7.1. Capsule
7.2. Film
7.3. Injectable Solution
7.4. Patch
7.5. Tablet
8. Addiction Disorders Drugs Market, by Drug Class
8.1. Alcohol
8.1.1. Acamprosate
8.1.2. Disulfiram
8.1.3. Naltrexone
8.2. Nicotine
8.3. Opioid
8.3.1. Buprenorphine
8.3.2. Methadone
8.3.3. Naltrexone
9. Addiction Disorders Drugs Market, by Product Type
9.1. Branded
9.2. Generic
10. Addiction Disorders Drugs Market, by Administration Route
10.1. Injectable
10.2. Oral
10.3. Sublingual
10.4. Transdermal
11. Addiction Disorders Drugs Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Addiction Disorders Drugs Market, by End User
12.1. Clinics
12.2. Homecare Settings
12.3. Hospitals
13. Asia-Pacific Addiction Disorders Drugs Market
14. Europe Addiction Disorders Drugs Market
15. North America Addiction Disorders Drugs Market
16. Latin America Addiction Disorders Drugs Market
17. Africa Addiction Disorders Drugs Market
18. Middle East Addiction Disorders Drugs Market
19. NATO Addiction Disorders Drugs Market
20. G7 Addiction Disorders Drugs Market
21. BRICS Addiction Disorders Drugs Market
22. European Union Addiction Disorders Drugs Market
23. ASEAN Addiction Disorders Drugs Market
24. GCC Addiction Disorders Drugs Market
25. China Addiction Disorders Drugs Market
26. United States Addiction Disorders Drugs Market
27. Japan Addiction Disorders Drugs Market
28. India Addiction Disorders Drugs Market
29. Germany Addiction Disorders Drugs Market
30. United Kingdom Addiction Disorders Drugs Market
31. Australia Addiction Disorders Drugs Market
32. France Addiction Disorders Drugs Market
33. South Korea Addiction Disorders Drugs Market
34. Italy Addiction Disorders Drugs Market
35. Canada Addiction Disorders Drugs Market
36. Russia Addiction Disorders Drugs Market
37. Brazil Addiction Disorders Drugs Market
38. Mexico Addiction Disorders Drugs Market
39. Spain Addiction Disorders Drugs Market
40. Competitive Landscape
40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025
41. Company Profiles
41.1. Accord Healthcare Limited
41.2. Alkermes plc
41.3. Amneal Pharmaceuticals Inc.
41.4. Aurobindo Pharma Limited
41.5. Bausch Health Companies Inc
41.6. BioCorRx Inc.
41.7. BioDelivery Sciences International Inc
41.8. Braeburn Inc.
41.9. Camurus AB
41.10. Cipla Limited
41.11. Dr. Reddy’s Laboratories Ltd
41.12. Eli Lilly and Company
41.13. Elite Pharmaceuticals Inc.
41.14. GlaxoSmithKline PLC
41.15. Glenmark Pharmaceuticals
41.16. H. Lundbeck A/S
41.17. Hikma Pharmaceuticals PLC
41.18. Indivior PLC
41.19. Insys Therapeutics Inc
41.20. Johnson & Johnson
41.21. Mallinckrodt Pharmaceuticals PLC
41.22. Novartis AG
41.23. Orexo AB
41.24. Pear Therapeutics
41.25. Pfizer Inc
41.26. Purdue Pharma L.P.
41.27. Reckitt Benckiser Pharmaceuticals Inc
41.28. Sun Pharmaceutical Industries Ltd
41.29. Teva Pharmaceutical Industries Ltd
41.30. Titan Pharmaceuticals Inc
41.31. Viatris Inc
List of Figures
FIGURE 1. GLOBAL ADDICTION DISORDERS DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ADDICTION DISORDERS DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ADDICTION DISORDERS DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ADDICTION DISORDERS DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ADDICTION DISORDERS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL ADDICTION DISORDERS DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 25. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. JAPAN ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. INDIA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. AUSTRALIA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. SOUTH KOREA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ADDICTION DISORDERS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ADDICTION DISORDERS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL ADDICTION DISORDERS DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CAPSULE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CAPSULE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CAPSULE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL FILM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL FILM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL FILM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL INJECTABLE SOLUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL INJECTABLE SOLUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL INJECTABLE SOLUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL PATCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL PATCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL PATCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL TABLET MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL TABLET MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL TABLET MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ALCOHOL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ALCOHOL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ALCOHOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ACAMPROSATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ACAMPROSATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ACAMPROSATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL DISULFIRAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL DISULFIRAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL DISULFIRAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL NALTREXONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL NALTREXONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL NALTREXONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL NICOTINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL NICOTINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL NICOTINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL OPIOID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL OPIOID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL OPIOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL BUPRENORPHINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL BUPRENORPHINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL BUPRENORPHINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL METHADONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL METHADONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL METHADONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NALTREXONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NALTREXONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NALTREXONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL BRANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL GENERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL SUBLINGUAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL SUBLINGUAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL SUBLINGUAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL TRANSDERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL TRANSDERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL TRANSDERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 101. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 103. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 104. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 105. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 106. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 107. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 108. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 109. EUROPE ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 128. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 129. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 130. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 131. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 132. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 133. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 134. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 135. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 136. AFRICA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 141. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 142. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 144. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. MIDDLE EAST ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 147. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 148. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 149. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 150. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 151. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 152. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 153. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 154. NATO ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 155. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 156. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 157. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 158. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 159. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 160. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 161. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 162. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 163. G7 ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 164. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 165. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 166. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 167. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 168. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 169. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 170. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 171. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 172. BRICS ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 176. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 177. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 178. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 183. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 184. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 185. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 186. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 187. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 188. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 189. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 190. ASEAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 191. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 192. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 193. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 194. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 195. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 196. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 197. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 198. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 199. GCC ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 200. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 201. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 202. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 203. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 204. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 205. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 206. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 207. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 208. CHINA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 209. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 210. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 211. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 212. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 213. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 214. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 215. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 216. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 217. UNITED STATES ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 218. JAPAN ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 219. JAPAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 220. JAPAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 221. JAPAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 222. JAPAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 223. JAPAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 224. JAPAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 225. JAPAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 226. JAPAN ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 227. INDIA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 228. INDIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 229. INDIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 230. INDIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 231. INDIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 232. INDIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 233. INDIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 234. INDIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 235. INDIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 236. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 237. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 238. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 239. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 240. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 241. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 242. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 243. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 244. GERMANY ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 245. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 246. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 247. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 248. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 249. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 250. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 251. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 252. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 253. UNITED KINGDOM ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 254. AUSTRALIA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 255. AUSTRALIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 256. AUSTRALIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 257. AUSTRALIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 258. AUSTRALIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 259. AUSTRALIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 260. AUSTRALIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 261. AUSTRALIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 262. AUSTRALIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 263. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 264. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 265. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 266. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 267. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 268. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 269. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 270. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 271. FRANCE ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 272. SOUTH KOREA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 273. SOUTH KOREA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 274. SOUTH KOREA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 275. SOUTH KOREA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 276. SOUTH KOREA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 277. SOUTH KOREA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 278. SOUTH KOREA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 279. SOUTH KOREA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 280. SOUTH KOREA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 281. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 282. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 283. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 284. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 285. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 286. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 287. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 288. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 289. ITALY ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 290. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 291. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 292. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 293. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 294. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 295. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 296. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 297. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 298. CANADA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 299. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 300. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 301. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 302. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 303. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 304. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 305. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 306. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 307. RUSSIA ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 308. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 309. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 310. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 311. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 312. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 313. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 314. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 315. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 316. BRAZIL ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 317. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 318. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 319. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 320. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 321. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 322. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 323. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 324. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 325. MEXICO ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 326. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 327. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 328. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 329. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY ALCOHOL, 2018-2032 (USD MILLION)
TABLE 330. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY OPIOID, 2018-2032 (USD MILLION)
TABLE 331. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 332. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 333. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 334. SPAIN ADDICTION DISORDERS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Addiction Disorders Drugs market report include:
  • Accord Healthcare Limited
  • Alkermes plc
  • Amneal Pharmaceuticals Inc.
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc
  • BioCorRx Inc.
  • BioDelivery Sciences International Inc
  • Braeburn Inc.
  • Camurus AB
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd
  • Eli Lilly and Company
  • Elite Pharmaceuticals Inc.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals
  • H. Lundbeck A/S
  • Hikma Pharmaceuticals PLC
  • Indivior PLC
  • Insys Therapeutics Inc
  • Johnson & Johnson
  • Mallinckrodt Pharmaceuticals PLC
  • Novartis AG
  • Orexo AB
  • Pear Therapeutics
  • Pfizer Inc
  • Purdue Pharma L.P.
  • Reckitt Benckiser Pharmaceuticals Inc
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Titan Pharmaceuticals Inc
  • Viatris Inc

Table Information

Report AttributeDetails
No. of Pages182
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 22.31 Billion
Forecasted Market Value ( USD ) by 2032 $ 39.33 Billion
Compound Annual Growth Rate9.8%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

Addictions Therapeutics Market Report 2026 - Product Image

Addictions Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Addiction Therapeutics - Global Strategic Business Report - Product Image

Addiction Therapeutics - Global Strategic Business Report

  • Report
  • 281 Pages
  • Global
From
Addiction Treatment - Global Strategic Business Report - Product Image

Addiction Treatment - Global Strategic Business Report

  • Report
  • 242 Pages
  • Global
From
Addiction Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Addiction Treatment Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Drug Addiction Treatment Market Report 2026 - Product Image

Drug Addiction Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.